Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018;20(9):E826-833. doi:
10.1001/amajethics.2018.826.
Adhering too strictly to biomedical thinking about diagnosis can prevent clinicians from empathically engaging with patients and helping them navigate their illness experiences.
AMA J Ethics. 2021;23(7):E537-541. doi:
10.1001/amajethics.2021.537.